In this study we also demonstrated the underlying mechanism of action (Fig. 12) of this phytochemical and its therapeutic approaches to combat dyslipidemia from the route via the AMPK and SREBP-1C gene interconnecting pathway. Here, SREBF1 is linked to metabolic syndrome.